NULIBRY is a first-in-class synthetic cPMP substrate replacement therapy to reduce the risk of mortality in patients with MoCD Type A
The approval marks a significant milestone for the American pharmaceutical company in the field of UC
The company had earlier announced about the approval received from the MHRA for Liraglutide
Liraglutide is a drug-device combination formulation used in the treatment of Type 2 Diabetes Mellitus
Ukrainian marketing approvals for paclitaxel, oxaliplatin and irinotecan mark a significant milestone in the company’s global expansion strategy
Versavo is the first Dr. Reddy's biosimilar product to be approved and launched in the UK
These approvals mark significant progress for Venus Remedies in expanding its market presence
BHL will undertake the development and supply of these molecules
Global TB incidence saw a reduction of 8.7% while in India we were able to demonstrate a reduction of 16%, almost double the pace
Tornado will enhance Bruker’s biopharma PAT portfolio with its well-established products
Subscribe To Our Newsletter & Stay Updated
_256_275.jpg)